![Bucharest, Romania - February 1, 2022: Illustrative editorial concept image of oral antiviral drug pill Paxlovid developed by Pfizer. Corona virus Cov Stock Photo - Alamy Bucharest, Romania - February 1, 2022: Illustrative editorial concept image of oral antiviral drug pill Paxlovid developed by Pfizer. Corona virus Cov Stock Photo - Alamy](https://c8.alamy.com/comp/2J6E5FM/bucharest-romania-february-1-2022-illustrative-editorial-concept-image-of-oral-antiviral-drug-pill-paxlovid-developed-by-pfizer-corona-virus-cov-2J6E5FM.jpg)
Bucharest, Romania - February 1, 2022: Illustrative editorial concept image of oral antiviral drug pill Paxlovid developed by Pfizer. Corona virus Cov Stock Photo - Alamy
![United States - december, 16, 2021: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study Stock Illustration | Adobe Stock United States - december, 16, 2021: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study Stock Illustration | Adobe Stock](https://as2.ftcdn.net/v2/jpg/04/77/27/83/1000_F_477278328_CL1Ei44Vii24K7gWgUddu2h3OFFKMJ1j.jpg)
United States - december, 16, 2021: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study Stock Illustration | Adobe Stock
![United States - december, 16, 2021: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study Stock Photo | Adobe Stock United States - december, 16, 2021: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study Stock Photo | Adobe Stock](https://as2.ftcdn.net/v2/jpg/04/76/93/15/1000_F_476931596_dtRX6ysv4LWk9FxuGAmtb2pZKxCL6oiU.jpg)